Hemispherx BioPharma, Inc (NYSE:HEB) was the target of a large increase in short interest in September. As of September 29th, there was short interest totalling 1,100,251 shares, an increase of 17.2% from the September 15th total of 938,792 shares. Based on an average daily volume of 263,493 shares, the short-interest ratio is currently 4.2 days. Approximately 4.0% of the company’s stock are short sold.

A hedge fund recently raised its stake in Hemispherx BioPharma stock. Vanguard Group Inc. grew its position in Hemispherx BioPharma, Inc (NYSE:HEB) by 0.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 453,805 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,709 shares during the quarter. Vanguard Group Inc. owned approximately 1.56% of Hemispherx BioPharma worth $227,000 as of its most recent SEC filing.

Hemispherx BioPharma (HEB) traded up 6.8837% during midday trading on Tuesday, reaching $0.3447. 259,703 shares of the company were exchanged. The firm’s 50-day moving average is $0.34 and its 200-day moving average is $0.48. Hemispherx BioPharma has a one year low of $0.30 and a one year high of $1.20. The firm’s market cap is $10.05 million.

Hemispherx BioPharma (NYSE:HEB) last released its quarterly earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter. Hemispherx BioPharma had a negative net margin of 1,029.58% and a negative return on equity of 75.57%. The firm had revenue of $0.21 million during the quarter. On average, equities analysts expect that Hemispherx BioPharma will post $0.00 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Hemispherx BioPharma, Inc (HEB) Short Interest Up 17.2% in September” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/10/hemispherx-biopharma-inc-heb-short-interest-up-17-2-in-september.html.

About Hemispherx BioPharma

Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.

Receive News & Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.